Skip to main content
Journal cover image

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Publication ,  Journal Article
Davies, MJ; D'Alessio, DA; Fradkin, J; Kernan, WN; Mathieu, C; Mingrone, G; Rossing, P; Tsapas, A; Wexler, DJ; Buse, JB
Published in: Diabetologia
December 2018

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Diabetologia

DOI

EISSN

1432-0428

Publication Date

December 2018

Volume

61

Issue

12

Start / End Page

2461 / 2498

Location

Germany

Related Subject Headings

  • United States
  • Sodium-Glucose Transporter 2 Inhibitors
  • Renal Insufficiency, Chronic
  • Liraglutide
  • Insulin
  • Hypoglycemic Agents
  • Hyperglycemia
  • Humans
  • Heart Failure
  • Glucagon-Like Peptide-1 Receptor
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., … Buse, J. B. (2018). Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 61(12), 2461–2498. https://doi.org/10.1007/s00125-018-4729-5
Davies, Melanie J., David A. D’Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J. Wexler, and John B. Buse. “Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia 61, no. 12 (December 2018): 2461–98. https://doi.org/10.1007/s00125-018-4729-5.
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018 Dec;61(12):2461–98.
Davies, Melanie J., et al. “Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia, vol. 61, no. 12, Dec. 2018, pp. 2461–98. Pubmed, doi:10.1007/s00125-018-4729-5.
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018 Dec;61(12):2461–2498.
Journal cover image

Published In

Diabetologia

DOI

EISSN

1432-0428

Publication Date

December 2018

Volume

61

Issue

12

Start / End Page

2461 / 2498

Location

Germany

Related Subject Headings

  • United States
  • Sodium-Glucose Transporter 2 Inhibitors
  • Renal Insufficiency, Chronic
  • Liraglutide
  • Insulin
  • Hypoglycemic Agents
  • Hyperglycemia
  • Humans
  • Heart Failure
  • Glucagon-Like Peptide-1 Receptor